Tags

Type your tag names separated by a space and hit enter

Estrogen replacement and migraine.
Maturitas. 2009 May 20; 63(1):51-5.M

Abstract

Four of every 10 women will experience migraine at some time in their lives, with peak prevalence in middle life. Evidence supports estrogen 'withdrawal' as one of the important triggers of menstrual attacks of migraine without aura. Improvement of migraine without aura postmenopause is generally attributed to the absence of variations in sex hormone levels. Maintaining a stable estrogen environment is best achieved using non-oral estrogen replacement. Unlike migraine without aura, migraine with aura is recognized as a marker for increased risk of ischemic stroke. Research suggests that aura may be more likely to affect women with underlying coagulation disorders. This could, at least in part, account for both increased risk of stroke and the dose related effect of estrogen replacement on the development of aura. Hence women with migraine with aura requiring estrogen replacement should be given the lowest effective dose necessary to control menopause symptoms, by a non-oral route.

Authors+Show Affiliations

The City of London Migraine Clinic, United Kingdom. anne.macgregor747@migraineclinic.org

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

19375252

Citation

MacGregor, E A.. "Estrogen Replacement and Migraine." Maturitas, vol. 63, no. 1, 2009, pp. 51-5.
MacGregor EA. Estrogen replacement and migraine. Maturitas. 2009;63(1):51-5.
MacGregor, E. A. (2009). Estrogen replacement and migraine. Maturitas, 63(1), 51-5. https://doi.org/10.1016/j.maturitas.2009.03.016
MacGregor EA. Estrogen Replacement and Migraine. Maturitas. 2009 May 20;63(1):51-5. PubMed PMID: 19375252.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Estrogen replacement and migraine. A1 - MacGregor,E A, Y1 - 2009/04/16/ PY - 2009/02/20/received PY - 2009/03/15/revised PY - 2009/03/16/accepted PY - 2009/4/21/entrez PY - 2009/4/21/pubmed PY - 2009/8/6/medline SP - 51 EP - 5 JF - Maturitas JO - Maturitas VL - 63 IS - 1 N2 - Four of every 10 women will experience migraine at some time in their lives, with peak prevalence in middle life. Evidence supports estrogen 'withdrawal' as one of the important triggers of menstrual attacks of migraine without aura. Improvement of migraine without aura postmenopause is generally attributed to the absence of variations in sex hormone levels. Maintaining a stable estrogen environment is best achieved using non-oral estrogen replacement. Unlike migraine without aura, migraine with aura is recognized as a marker for increased risk of ischemic stroke. Research suggests that aura may be more likely to affect women with underlying coagulation disorders. This could, at least in part, account for both increased risk of stroke and the dose related effect of estrogen replacement on the development of aura. Hence women with migraine with aura requiring estrogen replacement should be given the lowest effective dose necessary to control menopause symptoms, by a non-oral route. SN - 1873-4111 UR - https://www.unboundmedicine.com/medline/citation/19375252/Estrogen_replacement_and_migraine_ DB - PRIME DP - Unbound Medicine ER -